Notes to the Condensed Consolidated Interim Financial Statements of the Bayer Group

Key Data by Segment

Key Data by Segment

 

 

Pharmaceuticals

 

Consumer Health

 

Crop Science

 

Animal Health

 

 

Q1 2017

Q1 2018

 

Q1 2017

Q1 2018

 

Q1 2017

Q1 2018

 

Q1 2017

Q1 2018

 

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

1

For definition see Annual Report 2017, Chapter “Alternative Performance Measures Used by the Bayer Group.”

Net sales (external)

 

4,263

4,075

 

1,601

1,409

 

3,120

2,861

 

440

414

Change1

 

+9.6%

−4.4%

 

+5.3%

−12.0%

 

+6.3%

−8.3%

 

+7.8%

−5.9%

Currency-adjusted change1

 

+7.4%

+2.7%

 

+2.6%

−2.2%

 

+3.2%

−1.0%

 

+4.7%

+3.0%

Intersegment sales

 

10

9

 

5

1

 

8

8

 

1

2

Net sales (total)

 

4,273

4,084

 

1,606

1,410

 

3,128

2,869

 

441

416

EBIT1

 

1,219

1,163

 

278

211

 

970

892

 

126

129

EBIT before special items1

 

1,255

1,164

 

287

216

 

1,007

953

 

126

129

EBITDA before special items1

 

1,502

1,415

 

392

313

 

1,115

1,042

 

135

139

Net cash provided by operating activities

 

973

1,232

 

265

173

 

(679)

(703)

 

(31)

13

Depreciation, amortization, impairment losses / loss reversals

 

280

251

 

106

97

 

121

89

 

9

10

Key Data by Segment

 

 

Reconciliation

 

 

 

 

 

All Other Segments

 

Corporate Functions and Consolidation

 

Group

 

 

Q1 2017

Q1 2018

 

Q1 2017

Q1 2018

 

Q1 2017

Q1 2018

 

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

2017 figures restated

1

For definition see Annual Report 2017, Chapter “Alternative Performance Measures Used by the Bayer Group.”

Net sales (external)

 

252

378

 

4

1

 

9,680

9,138

Change1

 

+0.8%

+50.0%

 

 

+7.5%

−5.6%

Currency-adjusted change1

 

+2.0%

+48.0%

 

 

+5.0%

+1.9%

Intersegment sales

 

710

595

 

(734)

(615)

 

Net sales (total)

 

962

973

 

(730)

(614)

 

9,680

9,138

EBIT1

 

(26)

22

 

(140)

(107)

 

2,427

2,310

EBIT before special items1

 

(8)

30

 

(138)

(104)

 

2,529

2,388

EBITDA before special items1

 

45

87

 

(135)

(100)

 

3,054

2,896

Net cash provided by operating activities

 

(167)

(243)

 

190

186

 

551

658

Depreciation, amortization, impairment losses / loss reversals

 

53

57

 

3

4

 

572

508

Compare to Last Year